Best response to mogamulizumab (0.1, 0.3, or 1.0 mg/kg) by compartment for all evaluable CTCL patients and subgroups with Sézary syndrome and mycosis fungoides
| All evaluable CTCL patients (n = 38) . | Blood (n = 19) . | Skin (n = 38) . | Lymph nodes (n = 28) . | Global response (n = 38) . |
|---|---|---|---|---|
| ORR, n (%) [95% CI] | 18 (94.7) [74.0-99.9] | 16 (42.1) [26.4-59.2] | 7 (25.0) [10.7-44.9] | 14 (36.8) [21.8-54.0] |
| CR | 11 (57.9) | 4 (10.5) | 4 (14.3) | 3 (7.9) |
| PR | 7 (36.8) | 12 (31.6) | 3 (10.7) | 11 (28.9) |
| SD | 1 (5.3) | 20 (52.6) | 17 (60.7) | 19 (50.0) |
| PD | 0 (0) | 2 (5.3) | 4 (14.3) | 5 (13.2) |
| All evaluable CTCL patients (n = 38) . | Blood (n = 19) . | Skin (n = 38) . | Lymph nodes (n = 28) . | Global response (n = 38) . |
|---|---|---|---|---|
| ORR, n (%) [95% CI] | 18 (94.7) [74.0-99.9] | 16 (42.1) [26.4-59.2] | 7 (25.0) [10.7-44.9] | 14 (36.8) [21.8-54.0] |
| CR | 11 (57.9) | 4 (10.5) | 4 (14.3) | 3 (7.9) |
| PR | 7 (36.8) | 12 (31.6) | 3 (10.7) | 11 (28.9) |
| SD | 1 (5.3) | 20 (52.6) | 17 (60.7) | 19 (50.0) |
| PD | 0 (0) | 2 (5.3) | 4 (14.3) | 5 (13.2) |
| Subgroup with Sézary syndrome (n = 17) . | Blood (n = 17) . | Skin (n = 17) . | Lymph nodes (n = 15) . | Global response (n = 17) . |
|---|---|---|---|---|
| ORR, n (%) [95% CI] | 16 (94.1) [71.3-99.9] | 9 (52.9) [27.8-77.0] | 5 (33.3) [11.8-61.6] | 8 (47.1) [23.0-72.2] |
| CR | 9 (52.9) | 2 (11.8) | 2 (13.3) | 2 (11.8) |
| PR | 7 (41.2) | 7 (41.2) | 3 (20.0) | 6 (35.3) |
| SD | 1 (5.9) | 8 (47.1) | 7 (46.7) | 7(41.2) |
| PD | 0 (0) | 0 (0) | 3 (20.0) | 2 (11.8) |
| Subgroup with Sézary syndrome (n = 17) . | Blood (n = 17) . | Skin (n = 17) . | Lymph nodes (n = 15) . | Global response (n = 17) . |
|---|---|---|---|---|
| ORR, n (%) [95% CI] | 16 (94.1) [71.3-99.9] | 9 (52.9) [27.8-77.0] | 5 (33.3) [11.8-61.6] | 8 (47.1) [23.0-72.2] |
| CR | 9 (52.9) | 2 (11.8) | 2 (13.3) | 2 (11.8) |
| PR | 7 (41.2) | 7 (41.2) | 3 (20.0) | 6 (35.3) |
| SD | 1 (5.9) | 8 (47.1) | 7 (46.7) | 7(41.2) |
| PD | 0 (0) | 0 (0) | 3 (20.0) | 2 (11.8) |
| Subgroup with mycosis fungoides (n = 21) . | Blood (n = 2) . | Skin (n = 21) . | Lymph nodes (n = 13) . | Global response (n = 21) . |
|---|---|---|---|---|
| ORR, n (%) [95% CI] | 2 (100) [15.8-100] | 7 (33.3) [14.6-57.0] | 2 (15.4) [1.9-45.4] | 6 (28.6) [11.3-52.2] |
| CR | 2 (100) | 2 (9.5) | 2 (15.4) | 1 (4.8) |
| PR | 0 (0) | 5 (23.8) | 0 (0) | 5 (23.8) |
| SD | 0 (0) | 12 (57.1) | 10 (76.9) | 12 (57.1) |
| PD | 0 (0) | 2 (9.5) | 1 (7.7) | 3 (14.3) |
| Subgroup with mycosis fungoides (n = 21) . | Blood (n = 2) . | Skin (n = 21) . | Lymph nodes (n = 13) . | Global response (n = 21) . |
|---|---|---|---|---|
| ORR, n (%) [95% CI] | 2 (100) [15.8-100] | 7 (33.3) [14.6-57.0] | 2 (15.4) [1.9-45.4] | 6 (28.6) [11.3-52.2] |
| CR | 2 (100) | 2 (9.5) | 2 (15.4) | 1 (4.8) |
| PR | 0 (0) | 5 (23.8) | 0 (0) | 5 (23.8) |
| SD | 0 (0) | 12 (57.1) | 10 (76.9) | 12 (57.1) |
| PD | 0 (0) | 2 (9.5) | 1 (7.7) | 3 (14.3) |
CTCL, cutaneous T-cell lymphoma; PR, partial response; SD, stable disease.